CLN2 Disease

Also known as: Late-infantile Neuronal Ceroid Lipofuscinosis Type 2 (CLN2) / Neuronal ceroid lipofuscinosis type 2 / Neuronal Ceroid Lipofuscinosis Type 2 (CLN2) / CLN2 Disorder / Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2

DrugDrug NameDrug Description
DB13173Cerliponase alfaAn enzyme replacement therapy used to treat neuronal ceroid lipofuscinosis type 2 (CLN2) disease, also known as tripeptidyl peptidase 1 (TPP1) deficiency.
DrugDrug NamePhaseStatusCount
DB13173Cerliponase alfa1 / 2Active Not Recruiting1
DB13173Cerliponase alfa1 / 2Completed2
DB13173Cerliponase alfa2Completed1
DB13173Cerliponase alfaNot AvailableActive Not Recruiting1
DB13173Cerliponase alfaNot AvailableApproved for Marketing1